aducanumab
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Science envy comes in many flavors, and it is particularly easy to envy those who are privileged to discover simple stories. A…
Objective: We report 24-month data for fixed-dose and titration cohorts, including 12 months from the placebo-controlled period…
The pathological hallmarks of Alzheimer’s disease (AD) are the deposition of extracellular senile plaques resulting from amyloid…
Objective: To report interim results from a Phase 1b study (PRIME) for fixed-dose and titrated aducanumab. Background: Aducanumab…
iRGD (internalizing RGD) with high affinity to αν integrins was reported to enhance tumor penetrability by binding to neuropilin…
OBJECTIVE: To report interim data from the ongoing Phase 1b study (PRIME) in patients with Early Alzheimer’s Disease (AD) with…
Potential catalysts in the third quarter of 2015 include decisions by the US Food and Drug Administration (FDA) on the approval…